Segall Bryant & Hamill LLC Lowers Stake in Azenta, Inc. $AZTA

Segall Bryant & Hamill LLC lessened its position in Azenta, Inc. (NASDAQ:AZTA) by 14.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 478,339 shares of the company’s stock after selling 77,669 shares during the period. Segall Bryant & Hamill LLC’s holdings in Azenta were worth $10,107,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. boosted its position in Azenta by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 4,538,946 shares of the company’s stock worth $150,965,000 after acquiring an additional 99,588 shares during the last quarter. Conestoga Capital Advisors LLC raised its holdings in Azenta by 116.1% in the 1st quarter. Conestoga Capital Advisors LLC now owns 2,844,546 shares of the company’s stock valued at $60,105,000 after acquiring an additional 1,528,145 shares during the last quarter. Millennium Management LLC raised its holdings in Azenta by 9.9% in the 4th quarter. Millennium Management LLC now owns 1,866,531 shares of the company’s stock valued at $62,081,000 after acquiring an additional 167,969 shares during the last quarter. State Street Corp lifted its stake in shares of Azenta by 1.4% during the 4th quarter. State Street Corp now owns 1,732,755 shares of the company’s stock worth $57,631,000 after purchasing an additional 24,062 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Azenta by 16.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,613,914 shares of the company’s stock worth $34,183,000 after purchasing an additional 225,867 shares during the period. Hedge funds and other institutional investors own 99.08% of the company’s stock.

Azenta Stock Performance

Azenta stock opened at $28.13 on Monday. Azenta, Inc. has a 1 year low of $15.93 and a 1 year high of $41.73. The firm has a 50 day moving average price of $24.68 and a 200 day moving average price of $25.73. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -7.10 and a beta of 1.36.

Azenta (NASDAQ:AZTA) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.16). The company had revenue of $144.79 million for the quarter, compared to analysts’ expectations of $148.47 million. Azenta had a positive return on equity of 1.23% and a negative net margin of 30.49%.The business’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.01 EPS.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on AZTA. Needham & Company LLC lowered their price objective on Azenta from $44.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Weiss Ratings upgraded Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $40.40.

Azenta Profile

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.